Explore
Fundraising
MyLSTM
Clinical Diagnostic Parasitology Laboratory
Menu

James Dodd

Medical Statistician

I obtained my undergraduate degree in Physics from Durham University in 2000, and have worked in the field of clinical trials since 2008.

I worked from 2008-2018 at the Liverpool Cancer Trials Unit (LCTU), based at the University of Liverpool. In 2014 I obtained an M.Sc. in Quantitative Methods for Science, Social Science and Medicine from Lancaster University.
At the LCTU I worked variously as a data manager, trial coordinator, and statistician in medical statistics. I obtained wide experience in the design, setting-up, day-to-day running, and analysis of clinical trials and the ethical and regulatory conditions in which they are run. I also have experience of providing statistical support to other non-trial clinical research.
Disease areas of the studies on which I worked included haematological and pancreatic cancer, and chronic non-cancer conditions such as diabetes.

In April 2018 I joined the Tropical Clinical Trials Unit at LSTM as a medical statistician.

 

 

 

Selected publications

  • Small pancreatic ductal adenocarcinoma: a true clinical entity or an invalid diagnostic myth
    E Mohamed, J Dodd, P Ghaneh
    BRITISH JOURNAL OF SURGERY 104, 12-13

    Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
    Andrew R Pettitt, Richard Jackson, Stacey Carruthers, James Dodd, Susanna Dodd, Melanie Oates, Gillian G Johnson, Anna Schuh, Estella Matutes, Claire E Dearden, Daniel Catovsky, John A Radford, Adrian Bloor, George A Follows, Stephen Devereux, Anton Kruger, Julie Blundell, Samir Agrawal, David Allsup, Stephen Proctor, Earnest Heartin, David Oscier, Terry J Hamblin, Andrew Rawstron, Peter Hillmen
    Journal of Clinical Oncology 30 (14), 1647-1655

    Final Results of the Ncri Cll210 Trial of Alemtuzumab, Dexamethasone and Lenalidomide in Patients with High-Risk Cll (Original Protocol)
    AR Pettitt, Fotis Polydoros, James Dodd, Melanie Oates, Ke Lin, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Christina Yap, Sarah E Coupland, Peter Hillmen
    Haematologica 101, 726-726

    Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL
    R Pettitt, E Matutes, C Dearden, D Oscier, S Carruthers, J Dodd, S Dodd, R Jones, A Rawstrom, S Agrawal, D Allsup, A Bloor, J Blundell, S Devereux, G Follows, E Heartin, S Proctor, J Radford, T Hamblin, D Catovsky, P Hillmen
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 94, 138-139

    Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine‐based chemotherapy
    NTE Bird, M Elmasry, R Jones, E Psarelli, J Dodd, H Malik, W Greenhalf, N Kitteringham, P Ghaneh, JP Neoptolemos, D Palmer
    British Journal of Surgery 104 (4), 328-336

    A direct comparison of decision rules for early discharge of suspected acute coronary syndromes in the era of high sensitivity troponin
    Pei Gee Chew, Fredrick Frost, Liam Mullen, Michael Fisher, Heidar Zadeh, Ruth Grainger, Khaled Albouaini, James Dodd, Bilal Patel, Periaswamy Velavan, Babu Kunadian, Anju Rawat, Toba Obafemi, Sarah Tong, Julia Jones, Aleem Khand
    European Heart Journal: Acute Cardiovascular Care, 2048872618755369